



Nexia Biotechnologies Ltd.
P.O. Box 187, Jean-Talon Branch
Montreal, Quebec H1S 2Z2
www.nexiabiotech.com

Nexia provides Corporate Update and provides Third Quarter 2007 Results
(in Canadian dollars)

Edmonton, Alberta, Canada, April 25, 2007: Nexia Biotechnologies Ltd. ("Nexia") (CNQ: NXBL) today provided a corporate update and released financial results for the nine-month period ended February 28, 2007.

Corporate Update

Nexia's shares have commenced trading on Canada's new stock exchange, the CNQ, with the symbol NXBL. Shareholders may access the CNQ website at www.cnq.ca.

Enseco Energy Services Corp. has commenced trading on the TSXV, with the symbol ENS. A pro-rata distribution of 2,125,000 shares of Enseco to Nexia Biotechnologies Ltd. shareholders has been completed.

Nexia has been advised by management of PharmAthene Inc. that their proposed merger with Health Care Acquisition Corp. (AMEX: HAQ) is ongoing. Nexia currently has an approximate 10% equity interest in PharmAthene Inc. Under the proposed merger terms, it is expected that Nexia's equity will be issued with trading restrictions for up to 12 months from closing. Nexia shareholders are advised to follow developments in this transaction through the public announcements made by PharmAthene (www.pharmathene.com).

Nexia continues to pursue development of BioSteel® assets, having shipped product samples to several companies and institutions who are conducting preliminary investigations.

Third Quarter 2007 Financial Results

The loss for the quarter ended February 28, 2007 was \$180,000 (\$0.01 per share) or \$469,000 (\$0.02 per share) for the nine-month period then ended. The loss represents operations for the period from the asset transfer from Old Nexia to Nexia, from October 23, 2006 to February 28, 2007. No comparative figures have been presented as Nexia did not have operations in the previous year.

ABOUT NEXIA

For more information, please visit Nexia's website at www.nexiabiotech.com. Nexia's complete continuing disclosure documents, including: the third quarter 2007 report and interim financial statements, MD&A, can be accessed through Company's securities filings at www.sedar.com.

FORWARD-LOOKING STATEMENT AND OTHER IMPORTANT INFORMATION

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "intends"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. Nexia specifically disclaims any obligation to update these forward-looking statements. Nexia assumes no responsibility with respect to any information contained herein relating to any entity other than itself. Website addresses referred to herein are provided for convenience purposes only and information contained therein is not incorporated herein by reference, nor does Nexia assume any responsibility in connection therewith. For more information, please visit www.sedar.com. BioSteel® is a registered trademark of Nexia Biotechnologies Ltd., in Canada.

CONTACT INFORMATION

David L. Tonken, President, CEO and Chairman of the Board
tonken@icrossroads.com 780-486-2317